Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 1/20 | 0.41 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.39 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.39 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.39 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.39 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.39 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.39 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.39 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | EGFR known ✓ | P00533 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | EYA2 | O00167 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15442 | 0.94 | — | — | |
| Hydrochloric Acid SCHEMBL5560955 | 0.94 | — | — | |
| Hydrochloric Acid SCHEMBL4354108 | 0.91 | — | — | |
| SCHEMBL7055782 | 0.91 | — | — | |
| SCHEMBL716553 | 0.91 | TDP1 (0.47) | TDP1EYA2APPACEKDM4E | |
| SCHEMBL21778 | 0.91 | — | — | |
| SCHEMBL688403 | 0.88 | — | — | |
| SCHEMBL377745 | 0.88 | — | — | |
| SCHEMBL22115438 | 0.88 | — | — | |
| Water SCHEMBL21357760 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9968622-B2 | High-purity phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2018-05-15 | — | — | US | disclosed |
| US-20170246197-A1 | High-Purity Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2017-08-31 | — | — | US | disclosed |
| US-9566288-B2 | High-purity phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2017-02-14 | — | — | US | disclosed |
| EP-2604614-B1 | Oxidized phospholipids | VASCULAR BIOGENICS LTD (IL) | 2016-03-09 | — | — | EP | disclosed |
| US-20150216882-A1 | High-Purity Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2015-08-06 | — | — | US | disclosed |
| US-9006217-B2 | High-purity phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2015-04-14 | — | — | US | disclosed |
| US-8802875-B2 | Process for the preparation of oxidized phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2014-08-12 | — | — | US | disclosed |
| US-8569529-B2 | High-purity phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2013-10-29 | — | — | US | disclosed |
| EP-1773352-B1 | IMPROVED PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | VASCULAR BIOGENICS LTD (IL) | 2013-10-09 | — | — | EP | disclosed |
| US-20130237720-A1 | High-Purity Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2013-09-12 | — | — | US | disclosed |
| US-20130079540-A1 | High-Purity Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2013-03-28 | — | — | US | disclosed |
| US-20120130108-A1 | PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | VASCULAR BIOGENICS LTD. (IL) | 2012-05-24 | — | — | US | disclosed |
| US-8124800-B2 | Process for the preparation of oxidized phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2012-02-28 | — | — | US | disclosed |
| US-20100317881-A1 | PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | VASCULAR BIOGENICS LTD. (IL) | 2010-12-16 | — | — | US | disclosed |
| US-7807847-B2 | Process for the preparation of oxidized phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2010-10-05 | — | — | US | disclosed |
| EP-2125838-A2 | IMPROVED PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | Vascular Biogenics Ltd. (IL) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008084472-A2 | IMPROVED PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | VASCULAR BIOGENICS LTD. (IL) | 2008-07-17 | — | — | WO | disclosed |
| US-20070112211-A1 | Process for the preparation of oxidized phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2007-05-17 | — | — | US | disclosed |
| EP-1773352-A2 | IMPROVED PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | Vascular Biogenics Ltd. (IL) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006006161-A2 | IMPROVED PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | VASCULAR BIOGENICS LTD. (IL) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317881-A1 | PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | PHOSPHO1, SGMS1, SGMS2 | ACE 2653/4885CHRM2 3311/4885ADRA2A 3234/4885 |
| US-20130079540-A1 | High-Purity Phospholipids | PHOSPHO1, SGMS1, SGMS2 | ACE 3409/4885CHRM2 2362/4885ADRA2A 2366/4885 |
| US-20150216882-A1 | High-Purity Phospholipids | PHOSPHO1, SGMS1, SGMS2 | ACE 3497/4885CHRM2 2235/4885ADRA2A 1983/4885 |
| US-20170246197-A1 | High-Purity Phospholipids | PHOSPHO1, SGMS1, SGMS2 | ACE 3497/4885CHRM2 2235/4885ADRA2A 1983/4885 |
| US-20120130108-A1 | PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | PHOSPHO1, SGMS1, SGMS2 | ACE 2653/4885CHRM2 3311/4885ADRA2A 3234/4885 |
| US-20070112211-A1 | Process for the preparation of oxidized phospholipids | PHOSPHO1, SGMS1, SGMS2 | ACE 2653/4885CHRM2 3311/4885ADRA2A 3234/4885 |
| US-20130237720-A1 | High-Purity Phospholipids | PHOSPHO1, SGMS1, SGMS2 | ACE 3497/4885CHRM2 2235/4885ADRA2A 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.